
Paras Healthcare IPO: Listing Price, Subscription Status, Allotment & Dates
BSE/NSE · Mainboard
Paras Healthcare IPO at a glance
- Opens
- 21 Oct 2026
- Closes
- 23 Oct 2026
- Allotment
- 26 Oct 2026
- Listing
- 28 Oct 2026 · BSE/NSE
- Price band
- ₹660 – ₹693
- Lot size
- 21 shares (min ₹14,553)
- Issue size
- ₹1,450 Cr
- Registrar
- MUFG Intime India Pvt Ltd
Subscription: QIB 3.25x · NII 0.69x · Retail 2.1x · Total 2.34x (as of 16 Nov 2026, 9:00 PM IST)
GMP: ₹13 (1.88% of upper band) · estimated listing price ₹706 (updated 16 Nov 2026, 9:00 PM IST)
GMP is unofficial grey-market data and the listing estimate is simply upper band + GMP — not a prediction or advice.
Price Band
₹660 - ₹693
Lot Size
21 shares
Min ₹14,553
Issue Size
₹1,450 Cr
GMP (Grey Market)
₹13
1.9% premium
Important Dates
Open Date
21 Oct 2026
Close Date
23 Oct 2026
Allotment
26 Oct 2026
Listing
28 Oct 2026
Subscription Status
Day-by-Day Subscription
| Day | QIB | NII | Retail | Employee | Total |
|---|---|---|---|---|---|
| Day 1 (24 Oct 2026) | 3.25x | 0.69x | 2.10x | 0.00x | 2.34x |
| Day 2 (25 Oct 2026) | 3.25x | 0.69x | 2.10x | 0.00x | 2.34x |
| Day 3 (26 Oct 2026) | 3.25x | 0.69x | 2.10x | 0.00x | 2.34x |
| Day 4 (27 Oct 2026) | 3.25x | 0.69x | 2.10x | 0.00x | 2.34x |
GMP History
| Date | GMP (₹) | GMP (%) |
|---|---|---|
| 15 Oct 2026 | ₹115 | 16.6% |
| 16 Oct 2026 | ₹97 | 14.0% |
| 17 Oct 2026 | ₹96 | 13.8% |
| 18 Oct 2026 | ₹92 | 13.3% |
| 19 Oct 2026 | ₹84 | 12.1% |
| 20 Oct 2026 | ₹50 | 7.2% |
| 21 Oct 2026 | ₹35 | 5.0% |
| 22 Oct 2026 | ₹13 | 1.9% |
| 23 Oct 2026 | ₹11 | 1.6% |
| 24 Oct 2026 | ₹12 | 1.7% |
| 25 Oct 2026 | ₹12 | 1.7% |
| 26 Oct 2026 | ₹11 | 1.6% |
| 27 Oct 2026 | ₹17 | 2.5% |
| 28 Oct 2026 | ₹13 | 1.9% |
| 29 Oct 2026 | ₹13 | 1.9% |
| 30 Oct 2026 | ₹13 | 1.9% |
| 31 Oct 2026 | ₹13 | 1.9% |
| 1 Nov 2026 | ₹13 | 1.9% |
| 2 Nov 2026 | ₹13 | 1.9% |
| 3 Nov 2026 | ₹13 | 1.9% |
| 4 Nov 2026 | ₹13 | 1.9% |
| 5 Nov 2026 | ₹13 | 1.9% |
| 6 Nov 2026 | ₹13 | 1.9% |
| 14 Nov 2026 | ₹13 | 1.9% |
| 15 Nov 2026 | ₹13 | 1.9% |
| 16 Nov 2026 | ₹13 | 1.9% |
Paras Healthcare IPO allotment status
The basis of allotment is expected on 26 Oct 2026. The registrar to the issue is MUFG Intime India Pvt Ltd. Once allotment is final, shares are credited to your demat account before listing, and the blocked amount is released if you are not allotted.
Paras Healthcare IPO listing date
Paras Healthcare listed on 28 Oct 2026 on BSE/NSE. It listed at ₹720, +3.9% versus the ₹693 upper band.
Financial Performance
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | 1,129.04 | 1,294.06 | 1,605.95 |
| Profit (₹ Cr) | -15.33 | -57.98 | 43.83 |
| Total Assets (₹ Cr) | 1,477.66 | 1,810.45 | 2,017.14 |
As disclosed by Paras Healthcare in its offer document.
Strengths and risks
Taken from Paras Healthcare's own offer document — not Arthneeti's assessment.
- ✓As of June 30, 2026, the company operated eight hospitals with an aggregate bed capacity of 2,211 beds across five states and one Union Territory. It claims to have an early-mover advantage in several markets, including being the first corporate hospital entrant among its listed peers in Gurugram and Patna.
- !The company incurred losses of Rs 57.98 crore and Rs 15.33 crore in FY25 and FY24, respectively, and Rs 1.02 crore in the three months ended June 30, 2025. These losses were primarily attributable to the ramp-up of its Srinagar and Kanpur hospitals and investments in bed capacity expansion and clinical programmes across its hospital network. Although the company reported a profit of Rs 43.83 crore in FY26, any failure to increase revenue sufficiently to cover expenses and sustain profitability could adversely affect its financial performance.
- ✓The company focuses on cardiac sciences, oncology, neurosciences, gastro sciences, orthopaedics and sports injury, and renal sciences. These specialities contributed 74.70% of its revenue from operations in FY26, compared with 72.34% in FY24.
- !The company’s subsidiaries, Paras Healthcare (Ranchi) Private Limited and Plus Medicare Hospitals Private Limited, collectively incurred losses of Rs 20.38 crore, Rs 52.09 crore, Rs 82.24 crore, and Rs 87.27 crore in the three months ended June 30, 2025, FY26, FY25, and FY24, respectively. These losses were attributed to the ramp-up of the Ranchi and Srinagar hospitals and increased fixed and operating expenses following the expansion of bed capacity at the Ranchi hospital. Any failure of these subsidiaries to achieve profitability or raise adequate capital to meet their obligations could adversely affect the company’s financial performance.
12 more points from Paras Healthcare's offer document
About Paras Healthcare
Paras Healthcare is a hospital operator providing tertiary and quaternary healthcare services through a network of eight hospitals under the Paras Health brand. As of June 30, 2026, the company was present in five states and one Union Territory. Its hospitals are located in Gurugram and Panchkula in Haryana, Patna and Darbhanga in Bihar, Kanpur in Uttar Pradesh, Udaipur in Rajasthan, Ranchi in Jharkhand, and Srinagar in Jammu and Kashmir. The company provides treatments across several clinical specialities, including cardiac sciences, oncology sciences, neurosciences, gastro sciences, orthopaedics and sports injury, and renal sciences. As of June 30, 2026, its hospital network had 1,084 doctors and 1,937 nurses. Use of proceeds: The IPO consists of both a fresh issue of shares and an offer for sale (OFS). Proceeds from the OFS will go to the respective selling shareholders, whereas the net proceeds from the fresh issue will be utilised for the following purposes: Prepayment or scheduled repayment, in full or part, of certain outstanding borrowings availed by the company — Rs 320.90 crore Investment in the wholly owned subsidiary, PMHPL, for repayment/prepayment of borrowings, in full or part, of PMHPL — Rs 54.10 crore General corporate purposes
Go deeper on Paras Healthcare
See Arthneeti's AI earnings-call analysis, quarterly financials and quarter rank for Paras Healthcare.
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
GMP data is indicative and sourced from grey market. Subscription data is from exchange filings. This is not investment advice. Please consult a SEBI-registered advisor before investing.